Edoxaban noninferior to VKA in AF after PCI

Abstract

Edoxaban noninferior to VKA in AF after PCI Dual therapy with edoxaban plus a P2Y12 inhibitor is noninferior to triple therapy with a vitamin K antagonist (VKA) plus a P2Y12 inhibitor and aspirin for the risk of bleeding in patients with atrial fibrillation (AF) who had undergone percutaneous coronary intervention (PCI). These results from the ENTRUST-AF PCI trial were presented at the ESC Congress 2019. The trial was conducted in 18 countries and included 1,506 patients with AF who had had a successful PCI. Median time from PCI to randomization was 45.1 h. At 1 year, major or clinically relevant nonmajor bleeding events occurred in 17% and 20% of patients in the edoxaban and VKA groups, respectively (HR 0.83, 95% CI 0.65–1.05, P = 0.001 for noninferiority). Both groups had similar rates of the main efficacy outcome of ischaemic events.